These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. COX-2 selective nonsteroidal anti-inflammatory drugs and risk of gastrointestinal tract complications and myocardial infarction: an instrumental variable analysis. Davies NM; Smith GD; Windmeijer F; Martin RM Epidemiology; 2013 May; 24(3):352-62. PubMed ID: 23532054 [TBL] [Abstract][Full Text] [Related]
4. Issues in the reporting and conduct of instrumental variable studies: a systematic review. Davies NM; Smith GD; Windmeijer F; Martin RM Epidemiology; 2013 May; 24(3):363-9. PubMed ID: 23532055 [TBL] [Abstract][Full Text] [Related]
6. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. Warner TD; Mitchell JA Lancet; 2008 Jan; 371(9608):270-3. PubMed ID: 18207021 [No Abstract] [Full Text] [Related]
7. Response to invited commentary. Rose et al. respond to "G-computation and standardization in epidemiology". Rose S; Snowden JM; Mortimer KM Am J Epidemiol; 2011 Apr; 173(7):743-4. PubMed ID: 21415030 [No Abstract] [Full Text] [Related]
8. Do case control studies on coxibs tell us anything new? Brune K Rheumatology (Oxford); 2007 May; 46(5):730. PubMed ID: 17309891 [No Abstract] [Full Text] [Related]
9. Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice? Singh H South Med J; 2007 Aug; 100(8):856. PubMed ID: 17713322 [No Abstract] [Full Text] [Related]
10. Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes. Rassen JA; Schneeweiss S; Glynn RJ; Mittleman MA; Brookhart MA Am J Epidemiol; 2009 Feb; 169(3):273-84. PubMed ID: 19033525 [TBL] [Abstract][Full Text] [Related]
11. Challenges and opportunities for pharmacoepidemiology in drug-therapy decision making. Etminan M; Gill S; Fitzgerald M; Samii A J Clin Pharmacol; 2006 Jan; 46(1):6-9. PubMed ID: 16397278 [TBL] [Abstract][Full Text] [Related]
12. Getting to the heart of the matter: a trialist's approach to the use of nonsteroidal anti‑inflammatory drugs for patients with chronic pain syndromes. Farkouh ME Pol Arch Med Wewn; 2013; 123(9):433-5. PubMed ID: 24084249 [TBL] [Abstract][Full Text] [Related]
13. Variable selection for propensity score estimation via balancing covariates. Zhu Y; Schonbach M; Coffman DL; Williams JS Epidemiology; 2015 Mar; 26(2):e14-5. PubMed ID: 25643109 [No Abstract] [Full Text] [Related]
14. Commentary: regression discontinuity design: let's give it a try to evaluate medical and public health interventions. Vandenbroucke JP; le Cessie S Epidemiology; 2014 Sep; 25(5):738-41. PubMed ID: 25076150 [No Abstract] [Full Text] [Related]
15. Observational studies and the withdrawal of rofecoxib. Watson DJ; Santanello NC Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998 [No Abstract] [Full Text] [Related]
16. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734 [TBL] [Abstract][Full Text] [Related]
17. How statistics can be used to promote better health care. Sinclair J Nurs Times; 1999 Jun 23-29; 95(25):44-6. PubMed ID: 10497591 [No Abstract] [Full Text] [Related]
18. Differences between marginal structural models and conventional models in their exposure effect estimates: a systematic review. Suarez D; Borràs R; Basagaña X Epidemiology; 2011 Jul; 22(4):586-8. PubMed ID: 21540744 [TBL] [Abstract][Full Text] [Related]